Additional file 3: Table S2. of Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

All-grade AEs (occurring in ≥20 %) or grade ≥3 AEs (occurring in >3 %) of the total patient population in phase 1b. (PDF 72 kb)